Primo Nutraceuticals Inc. (CNSX:PRMO) signed a binding letter of intent to acquire Assets of Full Spectrum Biosciences, Inc. on November 12, 2020. The consideration for the transaction will be stipulated in the form of a number of common shares of Primo Nutraceuticals at a per share price equal to the volume weighted average price of such shares on the Canadian Securities Exchange over a 15-day period ending on the day such Consideration Shares are required to be issued. The consideration paid by Primo to Full Spectrum Biosciences for the transaction will be based on an independent valuation of the assets by a Third Party Valuator. The senior management team of Primo Nutraceuticals will consist of those officers presently appointed by the board of directors of Primo Nutraceuticals and shall remain the same. The transaction is subject to negotiation of a definitive agreement. The transaction is expected to before the end of fiscal year December 2020.